Theravance Biopharma Inc - Asset Resilience Ratio

Latest as of September 2025: 37.29%

Theravance Biopharma Inc (0TB) has an Asset Resilience Ratio of 37.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Theravance Biopharma Inc's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€154.91 Million
≈ $181.10 Million USD Cash + Short-term Investments

Total Assets

€415.46 Million
≈ $485.72 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Theravance Biopharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Theravance Biopharma Inc assets under control.

Liquid Assets Composition Over Time

This chart breaks down Theravance Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 0TB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €154.91 Million 37.29%
Total Liquid Assets €154.91 Million 37.29%

Asset Resilience Insights

  • Very High Liquidity: Theravance Biopharma Inc maintains exceptional liquid asset reserves at 37.29% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Theravance Biopharma Inc Industry Peers by Asset Resilience Ratio

Compare Theravance Biopharma Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%

Annual Asset Resilience Ratio for Theravance Biopharma Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Theravance Biopharma Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 14.27% €50.55 Million
≈ $59.10 Million
€354.16 Million
≈ $414.05 Million
-2.19pp
2023-12-31 16.46% €62.88 Million
≈ $73.51 Million
€382.00 Million
≈ $446.60 Million
+11.64pp
2022-12-31 4.83% €29.31 Million
≈ $34.27 Million
€607.40 Million
≈ $710.11 Million
-17.45pp
2021-12-31 22.28% €83.51 Million
≈ $97.63 Million
€374.82 Million
≈ $438.20 Million
-22.81pp
2020-12-31 45.08% €211.47 Million
≈ $247.24 Million
€469.06 Million
≈ $548.38 Million
-9.40pp
2019-12-31 54.49% €222.77 Million
≈ $260.44 Million
€408.83 Million
≈ $477.96 Million
+31.77pp
2018-12-31 22.71% €127.25 Million
≈ $148.77 Million
€560.24 Million
≈ $654.97 Million
-36.10pp
2017-12-31 58.81% €259.59 Million
≈ $303.48 Million
€441.40 Million
≈ $516.04 Million
+34.35pp
2016-12-31 24.46% €156.39 Million
≈ $182.83 Million
€639.25 Million
≈ $747.36 Million
+4.56pp
2015-12-31 19.90% €59.73 Million
≈ $69.83 Million
€300.12 Million
≈ $350.87 Million
-29.07pp
2014-12-31 48.97% €165.40 Million
≈ $193.37 Million
€337.77 Million
≈ $394.89 Million
--
pp = percentage points

About Theravance Biopharma Inc

F:0TB Germany Biotechnology
Market Cap
$864.92 Million
€739.82 Million EUR
Market Cap Rank
#9748 Global
#1199 in Germany
Share Price
€14.60
Change (1 day)
+0.00%
52-Week Range
€11.60 - €17.50
All Time High
€38.30
About

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more